The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Landsteiner Scientific pharmaceutical company have announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico (to cover 25% of population), RDIF informed.
Deliveries are expected to start in November 2020 subject to approval by Mexico's regulators. As part of the agreement with RDIF, Landsteiner Scientific as a partner of RDIF would distribute the vaccine in Mexico.
To recap, on August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19. On September 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine was published in one of the leading international medical journals The Lancet. Phase I and Phase II trials demonstrated no serious adverse events and a stable immune response in 100% of participants. Post-registration clinical trials of Sputnik V vaccine involving 40,000 volunteers are currently ongoing. First results of these trials are expected to be published in October-November 2020. Health safety of the human adenovirus vaccines has been proven by more than 75 international publications and 250 clinical trials showing greater safety track record of human adenoviral vectors versus novel unproven technologies such as monkey adenoviral vectors or mRNA.
Landsteiner Scientific, established in 1998, is a vertically integrated, privately held pharmaceutical company headquartered in Mexico City. The company's portfolio consists of more than 100 products and over 300 SKU's that cover the demand for the export market, private and the main public health institutions in Mexico.
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 70 projects with foreign partners totaling more than RUB 1.5 trillion and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than $40 billion.
